Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
暂无分享,去创建一个
A. Khera | M. Drazner | S. Murphy | J. D. de Lemos | Darren K Mcguire | Sandeep R. Das | D. McGuire | T. Omland
[1] D. Muthu,et al. Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .
[2] T. Hansen,et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. , 2007, European heart journal.
[3] R. Rodeheffer,et al. Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure , 2006, Hypertension.
[4] R. Rodeheffer,et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.
[5] P. Collinson,et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? , 2005, European heart journal.
[6] A. Khera,et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). , 2005, The American journal of cardiology.
[7] P. Hildebrandt,et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.
[8] M. Drazner,et al. Left Ventricular Hypertrophy Is More Prevalent in Blacks Than Whites in the General Population: The Dallas Heart Study , 2005, Hypertension.
[9] C. Camargo,et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.
[10] K. Khunti,et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. , 2005, Journal of the American College of Cardiology.
[11] Harald Becher,et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. , 2005, European heart journal.
[12] M. Drazner,et al. Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. , 2005, American heart journal.
[13] M. Nieminen,et al. Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.
[14] K. Bailey,et al. Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.
[15] Ronald M Peshock,et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. , 2004, The American journal of cardiology.
[16] D. Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .
[17] P. Hildebrandt,et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population , 2004, Heart.
[18] D. Levy,et al. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.
[19] M. Drazner,et al. B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.
[20] William J Catalona,et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.
[21] Daniel Levy,et al. The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.
[22] Douglas W Mahoney,et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.
[23] D. Levy,et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.
[24] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[25] D. Levy,et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.
[26] D. Morrow,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .
[27] R. Lancashire,et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.
[28] H. Hense,et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.
[29] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[30] L Irwig,et al. Meta-analysis of Pap test accuracy. , 1995, American journal of epidemiology.
[31] J. Gottdiener,et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. , 1995, American journal of hypertension.
[32] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[33] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[34] R. Doll,et al. The Epidemiology of Cancer , 1980, Cancer.